STUDIES OF THYROID DISEASES

关于使用低剂量阿霉素作为辐射的工作仍在继续。 增强剂提高I-131治疗高脂血症的疗效 有患甲状腺癌的风险。已有20名患者进入治疗方案，其中7人 随机接受联合治疗。共有19架I-131 与阿霉素联合使用的治疗方法没有发现 明显的附加毒性。 第二组甲状腺癌患者参加了一项研究，以 检测重组人促甲状腺激素刺激小鼠摄取的有效性 初次甲状腺切除术后残留的甲状腺。这个第一阶段和第二阶段 测试疗效和毒性的研究是多机构研究的一部分 与布鲁斯·温特劳布和Genzyme公司合作的努力。 初步结果正在评估中。 第三组甲状腺癌患者正在进行研究，以评估 用血清甲状腺球蛋白(TG)水平作为I-131治疗的指导 诊断全身I-131扫描结果为阴性的患者。十四 患者已经接受了最多三种使用150到300 mci i-131的治疗。 13例患者治疗后扫描呈阳性(其中21例 处理)。82%的患者血清甘油三酯下降，并恢复到较低水平 一次或两次治疗后，29%的患者血药浓度大于5ug/ml。《邮报》 治疗后50%的患者全身扫描呈阴性 三种疗法。

Work has continued on the use of low dose doxorubicin as a radiation enhancer to improve the effectiveness of I-131 in the treatment of high- risk thyroid cancer. Twenty patients have entered the protocol, 7 of whom were randomized to receive the combination therapy. A total of 19 I-131 treatments combined with adriamycin have been administered with no apparent additional toxicity. A second group of thyroid cancer patients has taken part in a study to test the effectiveness of recombinant human TSH to stimulate uptake in the thyroid remnant following initial thyroidectomy. This Phase I and II study to test efficacy and toxicity is part of a multi-institutional effort in collaboration with Bruce Weintraub and the Genzyme Corporation. The initial results are under evaluation. A third group of thyroid cancer patients are under study to evaluate the use of the serum thyroglubulin (TG) level as a guide to I-131 therapy in patients in whom a diagnostic whole body I-131 scan is negative. Fourteen patients have received up to three treatments with 150 to 300 mCi I-131 and the post therapy scan was positive in 13 patients (in 21 of 28 treatments). Serum TG decreased in 82% of patients, and reverted to less than 5 ug/ml in 29% of patients after one or two treatments. The post therapy whole body scan became negative in 50% of patients after two or three treatments.